Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Phase 2 Completed 39 enrolled Ionis Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of extended dosing with IONIS GHR-LRx in participants with acromegaly as add-on to somatostatin receptor ligands (SRL) therapy.

Timeline

Start: 2019-07-25
Primary completion: 2022-03-31
Completion: 2022-07-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IONIS GHR-LRx	Antisense oligonucleotide	—	Subcutaneous
Background	Lanreotide	Other / unclassified	—	—
Background	Octreotide	Peptide	—	—

Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Summary

Timeline

Drugs

Indications